Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
Background & Aims: Portal and hepatic vein tumor thrombosis is associated with inferior outcomes in patients with hepatocellular carcinoma (HCC), and systemic treatment alone is often insufficient. This phase II trial evaluated the efficacy and safety of combining sorafenib with radiotherapy...
Saved in:
Main Authors: | Yirui Zhai, Liming Wang, Hong Zhao, Fan Wu, Lingxia Xin, Feng Ye, Wei Sun, Yan Song, Lijuan Niu, Huiying Zeng, Jingbo Wang, Yuan Tang, Yongwen Song, Yueping Liu, Hui Fang, Ningning Lu, Hao Jing, Shunan Qi, Wenwen Zhang, Shulian Wang, Ye-Xiong Li, Jianxiong Wu, Bo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | JHEP Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S258955592400291X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion
by: Huang Shuaishuai, et al.
Published: (2018-12-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01) -
ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer
by: Yang-Hsiang Lin, et al.
Published: (2025-02-01) -
Sorafenib-Loaded Silica-Containing Redox Nanoparticle Decreases Tumorigenic Potential of Lewis Lung Carcinoma
by: Babita Shashni, et al.
Published: (2025-01-01)